Sydnexis

Myopia is the most common eye disease in children and has experienced a dramatic increase in prevalence over the last 30 years. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious ophthalmic co- morbidities. The greater myopia severity, the higher the risk of these ophthalmic co-morbidities later in life. Sydnexis was founded with the goal of developing a proprietary, stable, low-dose atropine eyedrop to treat myopia progression in children and minimize the risk of ocular co-morbidities. Formulation Matters! At Sydnexis, we have focused on developing a best-in-class low-dose atropine formulation to address...

Sydnexis operates in the Pharmaceutical manufacturing industry.

Sydnexis's revenue is 11m - 100m

Sydnexis has 11 - 50 employees.